Navidea Biopharmaceuticals (NAVB) Tops Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Navidea Biopharmaceuticals (NAVB) Files $100M Mixed Shelf; 3.17M Common for Shareholders
May 9, 2014 8:23 AM EDTNavidea Biopharmaceuticals (AMEX: NAVB) filed a registration with the U.S. SEC to sell, from time to time, up to $100 million of Common Stock, Preferred Stock, Warrants, Subscription Rights, Purchase Contracts, Units, or any combination thereof.
The company also filed to sell up... More
